LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

Strike Rare Diseases at the Root!

29/02/2020
BLOG

Strike Rare Diseases at the Root!

The 13th International Rare Disease Day is taking place on this year’s leap day, the 29th of February 2020. What started as a European initiative, organised by EURORDIS, soon grew out to be a global occasion to raise awareness of complex rare disorders. Any disease affecting fewer than 1 in 2,000 people in the EU is considered rare. More than 70% of the more than 6000 known rare diseases have a genetic origin and 70% start in childhood. Even though 1 in 20 people will live with a rare disease at some point in their life, there is still no diagnostic tool or cure available for 95 % of rare diseases.

Therapies developed for rare diseases are known as orphan medicines. The rare nature of these diseases presents significant barriers for the development of such medicines. The low prevalence of these conditions leads to limited knowledge about the diseases, difficulty in diagnosis, and complicates the design of clinical trials and limited access to specialists in the healthcare system. The EU has addressed some of these challenges in the year 2000 with the adoption of the Orphan Medicines Regulation. It offered, among others, scientific advice on study protocols (such as on how to meet the criteria for orphan designation), regulatory fee reductions (which are particularly helpful for SMEs) and incentives to stimulate development of treatments. Since the adoption of this legislation, more than 160 medicines have been authorised in the EU for use in rare conditions. But many more treatments are needed to really address the rare diseases challenges.

The fast advancement of bioscience and genomics in recent years has vastly increased our understanding of rare diseases. This has paved the way for the discovery of breakthrough novel treatments which tackle the genetic root cause of these diseases. For example, the discovery of the CRISPR-Cas9 technique is revolutionising medicine research and development and with this our response to complex genetic disorders. CRISPR makes it also possible to precisely add, remove or alter genetic material of the DNA, and thereby to correct a malfunctioning gene causing a rare genetic disease.

More than 30 million people and their families are affected by a rare disease in the EU. Since the EU took action in the field of rare disease 20 years ago, significant positive changes have occurred with innovative orphan medicinal products. The fact that only 5% of all rare diseases can be tackled today emphasizes the need for a continued joint effort to encourage transformative medicinal technologies in a Europe that supports innovation. EuropaBio is committed to contribute to addressing the remaining unmet needs of EU patients with challenging rare diseases.

Share
Alexandra Simionca
Alexandra Simionca

Related posts

07/07/2025

EuropaBio Position on the Critical Medicines Act


Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more
26/06/2025

EuropaBio AGM 2025: Association Chair, Executive Committee and Board announced


Read more

Important links

  • EuropaBio Position on the Critical Medicines Act
  • Life Sciences Strategy Embraces Biotech for Global Impact

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.